System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Axel Dignass is an expert in Gastroenterology at Agaplesion Markus Hospital (Germany). As of October 2026, ScienceLeadR ranks Axel Dignass in the top 1% of experts worldwide for Colitis, Inflammatory Bowel Diseases and Gastroenteritis. Axel Dignass has authored 551 publications, the most recent in 2026, and is an investigator in 18 clinical trials, 3 of them ongoing. SLR score: 2,104 (community average: 125). How the SLR is computed.

LeadR Profile

Axel Dignass Agaplesion Markus Hospital Germany
2 104 ScienceLeadR Reputation 2104

Unlock

Register Login
Network Map

Gastroenterology

Subspecialties: Hepatology - Pharmacy - Public Health

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 1993 - 2026
Source: PubMed

Agaplesion Markus Hospital

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 551

Citations

Citations: 33 892 1st author: 95 Last author: 103 Unique author: 7

Main journals

J Crohns Colitis 112
Z Gastroenterol 75
Gastroenterology 73
Am J Gastroenterol 29
Aliment Pharmacol Ther 22

Best Journals

Gastroenterology 6
Lancet Gastroenterol Hepatol 6
N Engl J Med 2

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
TREAT-TO-TARGET IN INFLAMMATORY BOWEL DISEASE: PROMISE, PERILS, AND THE PATH FORWARD.
PMID 42829018 — inflammatory bowel diseases, therapeutics		Clin Gastroenterol Hepatol20260
Positioning Guselkumab in The Treatment Algorithm for Ulcerative Colitis.
PMID 42609214 — interleukin-23, colitis, safety, algorithms, therapeutics, colitis, ulcerative		J Inflamm Res20260
Receptor interacting protein kinase 1 as a potential therapeutic target in inflammatory bowel disease: biological rationale and emerging clinical evidence.
PMID 42593061 — colitis, protein kinases, necroptosis, protein kinase inhibitors, inflammatory bowel diseases, therapeutics, colitis, ulcerative		Expert Opin Investig Drugs20260
IOIBD: the International Organization for the Study of Inflammatory Bowel Disease.
PMID 42553409 — inflammatory bowel diseases, research, education		Ther Adv Gastroenterol20260
Subcutaneous infliximab in the treatment of patients with perianal fistulizing Crohn's disease: current evidence and emerging roles.
PMID 42488031 — fistula, safety, crohn disease, therapeutics, infliximab		Ther Adv Gastroenterol20260

Clinical Studies 18

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 1

By phase:

Phase 3 8
N/A 3
Phase 2/Phase 3 3
Phase 2 2
Phase 1/Phase 2 1
Phase 4 1

By status:

Completed 10
Active not recruiting 2
Recruiting 2
Terminated 2
Not yet recruiting 1
Unknown 1

By type:

Interventional 15
Observational 3

By Monocentric/Multicentric:

monocentric 3
multicentric2to4 0
multicentric5to9 1
multicentricup10 14

Main Topics

Cohort/Consortium Investigators 1

Ongoing Clinical Trials

3 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
A Continuation Study of TAK 279 in Adults With Ulcerative Colitis (UC) and Crohn s Disease (CD)
2024-518914-18-00 — colitis, safety, crohn disease, therapeutics, colitis, ulcerative		Phase 2Not yet recruiting2025
Efficacy and Safety of Oral Controlled Ileocolonic Release Nicotinamide (CICR NAM) in Patients With Mild to Moderately Active Ulcerative Colitis
NCT06488625 — colitis, safety, niacinamide, maintenance, therapeutics, colitis, ulcerative		Phase 2/Phase 3Recruiting2024
A Phase 2 Study to Evaluate MORF 057 in Adults With Moderately to Severely Active Crohn s Disease
NCT06226883 — integrins, safety, crohn disease, inflammatory bowel diseases, small molecules		Phase 2Recruiting2024

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS